1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Kwality Pharmaceuticals Limited

Kwality Pharmaceuticals Limited

KPL.BO
Kwality Pharmaceuticals LimitedIN flagBombay Stock Exchange
2,548.05
INR
-105.15
- -
26.44BMarket Cap
Kwality Pharmaceuticals Limited
KPL.BO
(Bombay Stock Exchange)

Recent

price

2,548.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
57.43
50.48
74.05
191.3
132.23
160.3
134.25
252.57
439.65
241.93
295.94
356.4
- -
484.73
Revenue per Share
0.9
0.88
1.55
6.55
4.38
7.28
8.02
14.6
115.64
18.67
22.93
38.36
- -
64.9
Basic EPS, GAAP
-3.87
-0.34
-5.42
-4.86
-6.68
1.69
-14.08
3.19
5.25
-6.06
12.67
26.68
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.12
11.5
13.01
31.61
19.66
26.94
35.33
49.94
165.57
184.31
207.19
245.31
- -
10
Book Value per Share
17.11
18.39
21.31
48.85
27.72
35.01
43.33
57.69
173.27
191.85
214.51
250.97
- -
312.25
Tangible Book Value per Share
10
10
10
5
10
10
10
10
10
10
10
10
- -
10
Basic Weighted Avg Shares
596
524
742
983
1,372
1,663
1,393
2,620
4,562
2,510
3,071
3,702
5,031
5,031
Sales/Revenue/Turnover
3.91
4.35
5.38
7.94
6.37
7.57
8.45
8.65
35.29
18.23
15.24
16.77
19.57
19.57
Operating Margin (%)
12
13
17
25
30
31
44
65
107
150
196
183
198
198
Depreciation Expense
9
9
16
34
45
76
83
151
1,200
194
238
398
673
674
Net Income, GAAP
46.47
40.52
48.22
41.95
39.4
30.74
24.83
30.01
25.77
24.61
24.06
26.48
24.75
24.75
Effective Tax Rate (%)
1.57
1.75
2.09
3.42
3.31
4.54
5.97
5.78
26.3
7.72
7.75
10.76
13.39
13.39
Profit Margin (%)
71
70
116
115
130
145
213
276
883
813
908
1,143
1,802
1,802
Working Capital
14
8
27
33
47
76
102
183
203
273
196
151
294
294
LT Debt
178
191
213
251
288
363
450
599
1,798
1,991
2,226
2,624
3,299
3,299
Total Equity
- -
5.38
6.75
11.22
10.17
13.83
11.7
16.71
62.62
12.09
11.29
12.78
17.44
17.44
Return on Invested Capital (%)
- -
9.16
10.82
15.05
14.89
17.98
16.33
21.29
77.3
9.52
10.77
13.93
29.96
29.96
Return on Capital (%)
- -
8.17
12.44
22.99
24.82
31.24
25.75
34.24
107.33
10.67
11.72
16.96
50.79
50.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
964
- -
1,011
LT Borrowings
140
- -
294
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
- -
10
Market Capitalization
9,554
11,507
13,558

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,201
- -
4,057
Cash, Cash Equivalents & STI
469
- -
124
Accounts Receivable, Net
1,635
- -
2,801
Inventories
838
- -
783
Total Current Liabilities
1,706
- -
2,255
Payables & Accruals
- -
- -
- -
ST Debt
964
- -
1,011
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.19%
53.31%
25.73%
Free Cash Flow
-162.25%
-113.12%
-216.74%
Net Income, GAAP
107.77%
153.54%
69.02%
Sales/Revenue/Turnover
27.31%
21.59%
35.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
674
696
781
920
3,071
2025
801
900
844
1,157
3,702
2026
1,115
1,111
1,234
1,571
5,031

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.1
6.01
7.41
- -
22.93
2025
8.04
8.15
8.21
13.95
38.36
2026
11.49
13.6
15.42
24.39
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Boryung Corporation (003850.KS)
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS)
Jenkem Technology Co., Ltd. (688356.SS)
Chong Kun Dang Pharmaceutical Corp. (185750.KS)
ST Pharm Co.,Ltd. (237690.KQ)
Walgreens Boots Alliance, Inc. (WBA)
Business
Kwality Pharmaceuticals Limited manufactures and exports finished pharmaceutical formulations across diverse dosage forms including tablets, capsules, liquid orals, sterile powders for injection, ointments, ophthalmic suspensions, liquid injections, dry powders for oral suspension, lyophilized injections, vials, ampoules, eye/ear/nasal drops, creams, gels, suppositories, pre-filled syringes, bolus, and external preparations; the company specializes in complex generics, niche injectables, cephalosporins, beta-lactams, oncology products, and biologics such as Kwai Poietin, covering over 25 therapeutic areas like critical care, anaesthesia, cardiac, pain management, systemic anti-infectives, cytotoxic and allied products, sex hormones, and synthetic hormones, while also dealing in drug intermediates, chemicals, extracts, alkaloids, and other medical preparations. Headquartered in Amritsar, Punjab, India, with additional manufacturing facilities in Jassur, Himachal Pradesh, Kwality Pharmaceuticals operates from multiple specialized units including general, beta-lactam, cephalosporin, oncology, and biologics facilities, exporting to regulated and semi-regulated markets across Europe, Latin America, Africa, MENA, GCC, Russia, Asia, and CIS regions. Founded in 1983, the company holds prestigious certifications such as EU-GMP for four units (general, beta-lactam, cephalosporin, oncology), PIC/s GMP from Brazil, ANVISA, SFDA, WHO-GMP, INVIMA, COFEPRIS, and DIGEMID. Recent developments include successful EU-GMP audits for general and beta-lactam units at Amritsar in 2025, approval and commercialization of Leuprorelin Acetate 11.25 mg in Greece via a strategic CDMO partnership expected to generate USD 3 million in annual revenue starting January 2025, establishment of a biologics unit in 2023 with promising results for its first biologic Kwai Poietin, PIC/s approval for the beta-lactam unit, SFDA PIC/s approval for the general injectable unit, and DSIR approval for its Innovation Center R&D facility.